Bionano Genomics, Inc. (BNGO)

Bionano Genomics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	28.46	30.78	36.12	27.8	17.98	8.5
Revenue	28.46	30.78	36.12	27.8	17.98	8.5
Revenue Growth (YoY)	-24.04%	-14.79%	29.90%	54.62%	111.47%	-16.06%
Cost of Revenue	27.97	30.4	26.55	21.86	14.11	5.73
Gross Profit	0.49	0.38	9.57	5.95	3.87	2.77
Selling, General & Admin	41.16	51.86	94.22	86.48	56.92	29.57
Research & Development	17.39	24.8	54.03	49.05	22.49	10.26
Operating Expenses	58.55	76.66	148.25	135.53	79.41	39.82
Operating Income	-58.06	-76.28	-138.69	-129.58	-75.54	-37.05
Interest Expense	-2	-2.04	-5.12	-0.3	-0.93	-2.52
Interest & Investment Income	1.35	2.1	3.31	1.51	0.24	-
Other Non Operating Income (Expenses)	1.71	-4.69	-15.38	-0.12	-0.06	-0.01
EBT Excluding Unusual Items	-57	-80.9	-155.87	-128.5	-76.29	-39.58
Merger & Restructuring Charges	-3.39	-8.02	-0.74	-1.8	-1.5	-1.5
Impairment of Goodwill	-	-	-77.28	-	-	-
Gain (Loss) on Sale of Investments	-	-	-	-0.1	-	-
Asset Writedown	-19.24	-19.68	-	-	-	-
Other Unusual Items	-4.02	-3.38	1.46	-0.32	-0.37	-
Pretax Income	-83.64	-111.98	-232.43	-130.71	-78.15	-41.08
Income Tax Expense	0.06	0.03	0.06	1.88	-5.72	0.03
Net Income	-83.7	-112.02	-232.49	-132.6	-72.44	-41.11
Net Income to Common	-83.7	-112.02	-232.49	-132.6	-72.44	-41.11
Shares Outstanding (Basic)	2	1	1	0	0	0
Shares Outstanding (Diluted)	2	1	1	0	0	0
Shares Change (YoY)	160.18%	123.37%	18.05%	4.49%	165.50%	596.04%
EPS (Basic)	-48.53	-88.13	-408.60	-275.09	-157.02	-236.58
EPS (Diluted)	-48.53	-88.13	-408.60	-275.09	-157.02	-236.58
Free Cash Flow	-43.63	-69.03	-126.87	-128.02	-73.39	-38.31
Free Cash Flow Per Share	-25.30	-54.31	-222.97	-265.58	-159.09	-220.51
Gross Margin	1.74%	1.23%	26.49%	21.38%	21.55%	32.61%
Operating Margin	-203.98%	-247.85%	-384.00%	-466.09%	-420.08%	-435.74%
Profit Margin	-294.04%	-363.97%	-643.74%	-476.93%	-402.84%	-483.43%
Free Cash Flow Margin	-153.29%	-224.28%	-351.29%	-460.46%	-408.14%	-450.59%
EBITDA	-44.61	-62.26	-124.98	-119.96	-72.18	-35.57
EBITDA Margin	-156.73%	-202.29%	-	-	-	-
D&A For EBITDA	13.45	14.02	13.71	9.62	3.35	1.48
EBIT	-58.06	-76.28	-138.69	-129.58	-75.54	-37.05
EBIT Margin	-203.98%	-247.85%	-	-	-	-
Revenue as Reported	28.46	30.78	36.12	27.8	17.98	8.5

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q